Published in Drug Week, October 6th, 2000
The study enrolled more than 15,000 patients who were treated with Tequin (gatifloxacin), the quinolone antibiotic marketed by Bristol-Myers Squibb. The objective of the study was to validate the efficacy and safety of Tequin in the community setting.
"In the community setting, respiratory infections are usually treated empirically, and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.